EGFR and neoplasm: Therefore, an important question concerns the possibility to use CTCs as a non-invasive alternative of a new biopsy which could be more representative of the current biological status of tumor cells and might be used as a biomarker of either sensitivity or acquired resistance to EGFR targeted therapy.